Coronary artery bypass grafting significantly reduced the long-term risk of all-cause mortality (HR 0.63) compared to medical therapy in patients with chronic total occlusion and left ventricular systolic dysfunction.
Cohort (n=987)
No
Does CTO revascularization (PCI or CABG) improve long-term survival in patients with chronic total occlusion and left ventricular systolic dysfunction compared with medical therapy?
Hazard Ratio: 0.63 (95% CI 0.5–0.79)
Absolute Event Rate: 18.02% vs 29.92%
p-value: p=<0.001
BACKGROUND: The optimal treatment strategy for patients with coronary chronic total occlusion (CTO) and left ventricular systolic dysfunction (LVSD) remains unclear. This study investigated the long-term outcomes of percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), and medical therapy (MT) in this specific patient cohort. METHODS AND RESULTS: This retrospective cohort study included 987 consecutive patients with CTO and LVSD who met the inclusion criteria and underwent either CTO-PCI (n=277), CTO-CABG (n=222), or CTO-MT (n=488) between 2014 and 2020. The primary outcome was all-cause mortality during follow-up. Secondary endpoints were major adverse cardiac and cerebrovascular events (MACCE) and their components, including cardiovascular mortality, myocardial infarction (MI), stroke, unplanned revascularization, and hospitalization for heart failure. During a median follow-up of 5.3 years, 232 (23.51%) patients died from any cause. In the unadjusted analysis, CTO-MT was associated with worse long-term survival prospects. After inverse probability of treatment weighting and variable adjustment, CTO-PCI and CTO-CABG demonstrated significant reductions in the long-term risks of all-cause and cardiovascular mortality. Notably, CTO-CABG was associated with the lowest long-term risks of MACCE, MI, unplanned revascularization, and hospitalization for heart failure. CONCLUSIONS: For patients with CTO and LVSD, successful CTO revascularization significantly improved long-term survival compared with CTO-MT. CTO-CABG can be regarded as the optimal treatment modality for better long-term prognosis.
Zhang et al. (Wed,) conducted a cohort in Chronic total occlusion and left ventricular systolic dysfunction (n=987). Coronary artery bypass grafting (CTO-CABG) vs. Medical therapy (CTO-MT) was evaluated on All-cause mortality (HR 0.63, 95% CI 0.50-0.79, p=<0.001). Coronary artery bypass grafting significantly reduced the long-term risk of all-cause mortality (HR 0.63) compared to medical therapy in patients with chronic total occlusion and left ventricular systolic dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: